Novartis acquisition of Morphosys receives approval from Germany
Published: Tuesday, Mar 12th 2024, 11:30
Updated At: Tuesday, Mar 12th 2024, 11:50
Volver a Live Feed
Novartis podría adquirir la empresa alemana de biotecnología Morphosys. La Oficina Alemana de la Competencia dio luz verde a la compra el martes.
"We have examined very carefully that competition in the research and development of new drugs against a form of leukemia will not be impaired by the merger. As a result, we have no serious competition concerns," explained Andreas Mundt, President of the German Federal Cartel Office, in a press release.
Novartis anunció su intención de comprar Morphosys a principios de febrero y tiene previsto pagar 68,00 euros por acción. Esto eleva el precio de compra a 2.700 millones de euros.
The transaction gives Novartis access to pelabresib, a drug for the treatment of myelofibrosis (MF), a life-threatening chronic disease of the bone marrow. In a recent combination study, the active ingredient led to a reduction in spleen volume and thus achieved the targets set. In the USA, the application for approval from the US Food and Drug Administration (FDA) should be submitted in the second half of 2024 if possible.
©Keystone/SDA
Spanish 
English 
German 
French 
Arabic